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In the era of managing chronic kidney disease (CKD),
there is a pyramid of a large number of patients at risk
for renal failure who require renoprotection programs
and, at the same time, a much smaller number of
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In the management of chronic kidney disease (CKD), there is a large number of patients at risk for renal failure
who require renoprotection programs and, at the same time, a much smaller number of patients with end-stage
kidney disease who require very costly renal replacement programs. Among the exciting innovations with
regard to science and care in nephrology, the areas of prevention and cost-effective quality care of CKD patients
using peritoneal dialysis (PD) has seen many new developments, exemplified by work done in the Prince of
Wales Hospital in Hong Kong. However, while successes in PD have been achieved, there remain many areas
that require further improvement, such as technique failure, prevention and treatment of peritoneal infections,
peritoneal access, adequacy of solute removal, peritoneal physiology and changes with long-term PD, patient
fatigue, cardiovascular mortality, severe malnutrition, preservation of residual renal function, and metabolic
and inflammatory problems. The center in the Prince of Wales Hospital has focused on clinical and basic
science research to address these areas, with the aim of making PD a more cost-effective mode of renal
replacement therapy with excellent quality. The following areas are highlighted in this review: prevention and
treatment of peritonitis, the use of angiotensin-converting enzyme inhibitors in preserving residual renal function,
oral bicarbonate in improving acidosis and nutritional status, thiazolidinediones in reducing insulin resistance
and inflammation, and the use of biocompatible dialysis solutions in improving peritoneal membrane
permeability and reducing inflammation. [Hong Kong J Nephrol 2008;10(1):1–6]
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patients with end-stage kidney disease who require very
costly renal replacement programs (Figure). Among all
the exciting innovations with regard to science and care
in nephrology, the areas of prevention and cost-effective
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quality care of CKD patients using peritoneal dialysis
has seen many new developments, exemplified by work
done in the Prince of Wales Hospital (PWH), Hong
Kong.
Chronic diseases comprise the largest global cause
of death. In 2002, the leading chronic diseases caused
29 million deaths worldwide. This trend is likely to
increase in the next decade. CKD is causing similar
problems in the field of nephrology [1].
The World Health Organization has already
recognized that renal disease is a public health issue.
In 2000, there were about 1.5 million patients globally
on dialysis; in 2010, this number is projected to increase
to 2.5 million, a 7% increase year on year. A similar
trend is being observed in Hong Kong. The incidence
of end-stage renal failure requiring replacement therapy
has increased significantly around the world. Data from
the United States Renal Data System (USRDS) for the
year 2005 showed that Taiwan had an annual incidence
of 404 new cases per million population (pmp), the
highest in the world, which was followed by USA (351
new cases pmp) and Mexico (302 new cases pmp) [2].
In Hong Kong, the annual incidence was 173 new cases
pmp in 2005, taking the 13th place in the USRDS data.
The prevalence was 965 uremic patients pmp requiring
treatment in Hong Kong in 2005 [2]. However, if we
look into the breakdown by age group of the incidence
of new cases, Hong Kong should not be too complacent.
For the age group of 20–44, Hong Kong ranked number
4, after USA, Turkey and Taiwan, with 88 new cases
pmp. For the age group of 45–64, Hong Kong ranked
number 5, after Taiwan, USA, Turkey and Malaysia,
with 289 new cases pmp. This signifies that renal
disease is not at all uncommon in our relatively younger
population.
In 2005, 41% of the cases of end-stage renal disease
(ESRD) in Hong Kong were due to diabetes mellitus,
20% to nephritis, and 10% to hypertension. About 16%
were due to unknown etiologies, usually presenting with
late-stage renal failure [3]. This has prompted the
development of strategies aimed at preventing the
development and progression of asymptomatic CKD.
Community strategies to reduce the incidence of ESRD
integrate methods of screening and early intervention.
Issues surrounding the screening of CKD include: (i)
whom to screen; (ii) how to screen; and (iii) what to do
when screening shows an abnormality. The recent
International Society of Nephrology (ISN) Prevention
of Progression of Kidney Disease Consensus Statements
established in Hong Kong set 15 guidelines for
prevention [4]. (They can be retrieved from the ISN
website: http://www.nature.com/isn/education/
guidelines/isn/full/ed_051027_4.html.) It was
recommended that patients diagnosed with diabetes and
hypertension should have regular screening to detect
development of kidney disease [4]. The close relatives
of patients with nephropathy due to diabetes,
hypertension and glomerulonephritis should also be
primary targets for screening to detect clinically silent
kidney disease.
The Hong Kong Society of Nephrology had
conducted a screening program named SHARE: that
is, the Screening of Hong Kong Asymptomatic Renal
Population and Evaluation [5]. Among the 1,201
apparently “healthy”  subjects (asymptomatic and
without history of diabetes, hypertension or CKD), the
prevalence of positive (>1+) urine dipstick for protein,
glucose, blood, protein or blood, any urine abnormality,
and hypertension (blood pressure > 140/90 mmHg)
were 3.2%, 1.7%, 13.8%, 16%, 17.4% and 8.7%,
respectively. Thirty-three percent of the subjects > 60
years old had either hypertension or urine abnormalities,
compared with 24% in the 41–60 years old group and
9.7% in the 20–40 years old group. Having a family
history of diabetes or hypertension increased the risk
of having urine abnormalities, while a family history
of hypertension also increased the risk of high blood
pressure [5]. With such a high incidence of urine and
blood pressure abnormalities in the general population,
the high incidence of renal failure in the younger age
groups of 20–44 and 45–64 in Hong Kong as illustrated
in the USRDS 2005 data do not seem too surprising [2,
5]. An effective screening program at the primary care
level that identifies these subjects for further evaluation
is warranted.
Effective therapeutic measures are now available
which might prevent the progression of CKD [4].
These measures include: (i) lifestyle modification; (ii)
blood pressure control; (iii) glycemic control; (iv)
reduction of proteinuria; (v) protein restriction; (vi)
lipid lowering; (vii) avoidance of nephrotoxic agents;
Figure. Renoprotection programs for patients with chronic kidney
disease. The pyramid illustrates the importance of prevention for
a large patient population at risk and a cost-effective peritoneal
dialysis program for patients with end-stage renal disease (ESRD).
Hong Kong J Nephrol • April 2008 • Vol 10 • No 1 3
Prevention and peritoneal dialysis in nephrology
(viii) early referral to nephrologists; and (ix) other
measures (e.g. correction of anemia). The benefit of
using angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers in different
stages of renal failure in adult and childhood are
recognized [6,7]. In our ISN Consensus Statements,
it was also promulgated that traditional cardiovascular
disease risk factors should be screened in all patients
with CKD. These include documentation of smoking
history, measurement of blood pressure, body weight,
body mass index, fasting plasma glucose, fasting lipid
profi le ,  serum uric  acid level ,  and 12-lead
electrocardiogram. In our recent study of predialysis
patients with CKD, we found that in these patients
with a mean estimated glomerular filtration rate (GFR)
of 39.8 mL/min/1.73 m2, 46 of 203 patients (22.7%)
developed the primary composite end point of
cardiovascular disease after an average follow-up of
52.4 months [8], thus showing that in Chinese, the
problem of cardiovascular disease in predialysis CKD
patients is also significant.
In Hong Kong, IgA nephropathy accounts for about
45% of all cases of glomerulonephritis causing renal
failure requiring dialysis. Our center’s data showed that
the renal survival for IgA nephropathy was 92.0% at 1
year, 87.5% at 5 years and 81.8% at 10 years [9]. Our
recent HKVIN (Hong Kong Study using Valsartan in
IgA Nephropathy) study showed that valsartan
significantly reduced proteinuria and slowed renal
deterioration in patients with IgA nephropathy [6]. With
multiple linear regression models, valsartan treatment
resulted in a 33% decrease in proteinuria after adjusting
for other confounding factors. There was also a
significant decrease in the mean rate of GFR decline in
the valsartan-treated group (5.62 mL/min/year)
compared with the placebo group (6.98 mL/min/year)
throughout the study period [6].
Rising demand for dialysis therapy and its
associated costs are placing an unsustainable financial
burden on public sector health care budgets in
countries all over the world [10], which carry profound
implications for health care financing in the near
future. The predicted dialysis cost globally will
increase to about US$1.1 trillion for the decade of
2001–2010, compared with about US$500 billion
spent for the last decade worldwide [1]. An ideal renal
replacement therapy should have optimal survival,
lowest possible risk for comorbidity, highest level of
quality of life and, equally important, acceptable cost
for society [10]. Viable solutions are urgently needed
in managing the treatment of ESRD and controlling
spending on ESRD without compromising the quality
of patient care.
The model used in Hong Kong, the policy of using
continuous ambulatory peritoneal dialysis (CAPD) first,
is also being considered by other countries as an
appealing cost-effective modality [11–13]. The overall
survival of peritoneal dialysis (PD) patients in PWH is
very respectable, with a 2-year patient survival of 91%
and technique survival of 82% [12]. With an increasing
number of elderly ESRD patients, the 2-year and 5-
year patient survival rates for the elderly group in our
PD program were 89.3% and 54.8%, respectively,
which were comparable to the rate of survival in the
non-elderly group [14]. There are good reasons for why
the PD program is successful in Hong Kong. Many
patient factors affect survival in PD. In the general
population, genetics, diet, cultural practices, lifestyle
and socioeconomic status affect survival. In the PD
population, dialysis practices, dialysis prescriptions,
compliance with treatment, comorbid illnesses, body
size and peritoneal membrane transport all play major
roles that contribute to success and patient and
technique survival in PD [12]. Obviously, a committed
team of medical, nursing and supporting staff with
expertise in PD is essential, and it was found that a
center with a high number of PD patients would be
more likely to achieve this.
While successes in PD have been achieved, there
remain many areas that require further improvement,
as shown in the Table: technique failure, prevention and
treatment of peritoneal infections [15,16], peritoneal
access, adequacy of solute removal, peritoneal
physiology and changes with long-term PD, patient
fatigue, cardiovascular mortality [17], severe
malnutrition, preservation of residual renal function
[18] including the use of ACEIs [19], and metabolic
and inflammatory problems in PD patients.
Our center in PWH has focused on clinical and basic
science research to address these areas, with the aim of
making PD a more cost-effective mode of renal
replacement therapy with excellent quality. The
following areas will be highlighted below: prevention
and treatment of peritonitis, ACEIs in preserving
residual renal function, oral bicarbonate in improving
acidosis and nutritional status, thiazolidinediones in
reducing insulin resistance and inflammation, and the
use of biocompatible dialysis solutions in improving
peritoneal membrane permeability and reducing
inflammation.
Table. Current problems in peritoneal dialysis (PD) requiring
improvement
Technique failure and long-term PD
Peritoneal infections
Peritoneal access
Adequacy of solute removal
Peritoneal physiology and changes with long-term PD
Patient fatigue
Cardiovascular mortality
Severe malnutrition
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PREVENTION AND TREATMENT OF PERITONITIS
The fundamental concept of the disconnect system is
flush-before-fill, which carries with it any contaminating
bacteria introduced during connection. In the early
1990s, our center reported a better peritonitis rate and
cost-effectiveness with the Y-set disconnect system
versus the conventional spike system [20]. Double-bag
systems were then studied in our center, in which the
Y-set was replaced with a completely sterilized
disposable integrated system, which contained an empty
bag and a fresh dialysate-containing bag. The technique
of flush-before-fill was still used. It is better than the
Y-set theoretically as there are fewer connecting
procedures. Although the manufacturing cost of double-
bag systems is higher than that of the Y-set, the cost
savings for the treatment of peritonitis and related
hospitalization can be substantial. In a multicenter,
single-blinded, prospective randomized study on the
use of a double-bag disconnect system versus the Y-set
disconnect system, it was found that both systems had
a similar incidence of peritonitis and exit site infection,
but the double-bag system was better accepted by
patients [21]. Another innovative double-bag system
was then explored in PWH, in which the solution-
drainage bag and fresh-solution bag are connected to
tubing catheters by means of a special switch disc
device, which controls and regulates all three phases
of exchange: outflow, flush, and inflow [15]. This
system has a pin housed in the switch disc, and the pin
automatically closes the system to ensure safe sealing
of the transfer set at the end of the procedure. Both
double-bag systems showed comparably good clinical
outcomes, but the double-bag system with the special
switch disc device was easier to learn, at least during
the initial training period [15].
Early outcome prediction has major potential
implications regarding the management of dialysis-
related peritonitis. Our previous study found that a
peritoneal dialysate white count cut-off point > 1,090/
mm3 on day 3 was a good prediction value of treatment
failure (defined as catheter loss or peritonitis-related
death) [22]. The study demonstrated that peritoneal
dialysate white cell count on day 3 could predict the
outcome of dialysis-related peritonitis [22]. Effective
treatment of peritonitis is also important, and our study
comparing imipenem/cilastatin monotherapy with two
standard regimens of cefazolin plus ceftazidime or
netilmicin in the treatment of PD peritonitis found that
they had similar efficacy [23].
PHARMACOTHERAPY
Cardiovascular mortality and morbidity are common
in our PD patients [17]. Various drug treatments were
explored in PWH to improve the survival and wellbeing
of our CAPD patients. It has been well recognized that
residual  renal  function plays a  key role in
atherosclerosis, cardiovascular problems, inflammation
and nutrition in PD patients [18]. It is also an important
prognostic marker in CAPD patients. In patients with
diabetic nephropathy and chronic proteinuric
nephropathy, ACEIs reduce the rates of renal function
deterioration. A randomized prospective open-label
study showed that ramipril, an ACEI, was effective in
preserving the residual renal function of PD patients
[19]. Another important but commonly missed problem
in CAPD patients is persistent acidosis, which is a major
factor that contributes to malnutrition in renal failure
patients. Although correction of acidosis by high-lactate
dialysate improves the nutritional status and reduces
the hospitalization of CAPD patients, extensive use of
a high-lactate dialysate will result in alkalosis in some
patients, and the lactate concentration in the dialysate
cannot be adjusted according to need. Oral sodium
bicarbonate is a convenient alternative because the
dosage can be tailored easily. A randomized placebo-
controlled study in PWH of CAPD patients with
borderline dialysis adequacy showed that oral sodium
bicarbonate is effective in improving nutritional status
and reducing the duration of hospitalization in this
group of patients [24]. Treatment with oral bicarbonate
resulted in a higher level of plasma bicarbonate. The
overall Subjective Global Assessment Score of the
treatment group was higher than that of the placebo
group. Normalized protein nitrogen appearance rose in
the treatment group but declined in the placebo group
[24].
A systemic inflammatory state and diabetes are
both common problems in our CAPD patients.
Rosiglitazone, a new thiazolidinedione, is an
antidiabetic agent of the class peroxisome proliferator-
activated receptor modulator-gamma (PPAR-a) [25]. It
improves insulin resistance in patients with type 2
diabetes mellitus by increasing insulin sensitivity in the
liver, adipose tissue, and muscle. Moreover, PPAR-a
has anti-inflammatory and antiproliferative effects on
the vasculature. Our center evaluated the effect of
rosiglitazone in diabetic CAPD patients in a randomized
controlled trial, and showed that the drug reduced
insulin requirement and, more importantly, reduced the
degree of systemic inflammation as represented by
serum C-reactive protein level [25].
BIOCOMPATIBLE DIALYSIS SOLUTION
Chronic utilization of bioincompatible PD solution has
been implicated as a cause of progressive loss of
peritoneal membrane permeability. Acidic pH and
glucose degradation product (GDP) in conventional PD
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solution are the major factors of bioincompatibility. A
double-chamber bag system was studied in our center,
which utilized lactate-buffered PD solution in a two-
compartment bag [26]. The formation of GDP is greatly
reduced by separating the glucose component of the
solution (kept at very low pH) from the lactate
component of the solution (kept at alkaline pH) during
sterilization and storage. Immediately before infusion,
the seam between the two chambers is opened, and the
contents are mixed. The ready-to-use solution has a
physiologic pH in the range of 6.8 to 7.4, and a greatly
reduced amount of GDP. In a prospective randomized
controlled study, we found that the use of the
biocompatible low GDP solution resulted in a superior
profile of dialysis effluent mesothelial cell marker as
shown by a higher PD fluid CA125 and lower
hyaluronan A. It also resulted in a lower degree of
systemic inflammation as compared to conventional
dialysis solution as reflected by a lower serum C-
reactive protein level than in the control group [26].
EPILOGUE
As the President of the Organizing Committee for the
ISN 2004 Conference on the Prevention of Progression
of Renal Disease, I was pleased to see 1,269 delegates
from 39 countries around the world attending this
important conference with more than 40 invited
international renowned speakers and over 150 scientific
presentations. This was one of the biggest conferences
on the prevention of CKD. A special supplement on
the Prevention of Progression of Renal Disease was
published in Kidney International in April 2005.
In 2006, the 11th Congress of the International
Society for Peritoneal Dialysis (ISPD) was organized
in Hong Kong. I was honored again to be the President,
organizing this conference with 2,511 participants from
more than 70 countries. There were over 500
presentations on PD from 50 countries around the
world. Once again, this was one of the biggest ISPD
conferences ever held. A special supplement on
Achieving PD Excellence was published in Peritoneal
Dialysis International in June 2007. These two
conferences were important milestones in my journey
of prevention and PD and also contributed significantly
in the promulgation of knowledge in these two
important areas in nephrology to the world.
My journey in prevention and PD, through team
work with my own Division of Nephrology in the Prince
of Wales Hospital, Chinese University of Hong Kong
and colleagues in the Hong Kong Society of
Nephrology, has been extremely enjoyable, challenging
and innovative. The journey will go on with one key
objective: to further improve the wellbeing of renal
patients.
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